カテゴリ： GlobalData, カナダ, 企業調査

ProMetic Life Sciences Inc (PLI)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：ProMetic Life Sciences Inc (PLI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10126
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：90
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：カナダ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
ProMetic Life Sciences Inc (ProMetic) is a biopharmaceutical company that focuses on bioseparations, plasma-derived therapeutics and small-molecule drug development. The company develop products for the treatment for fibrosis, anemia, autoimmune diseases, inflammation and nephropathies. The company develops drug candidates based on its two drug discovery platforms: small molecule therapeutics (PSMT) and plasma-derived therapeutics platforms. The company owns research and development facilities in the UK, the US and Canada and has manufacturing facilities in Canada and the Isle of Man. The company conducts business development activities in the US, Europe and Asia. ProMetic is headquartered in Laval, Quebec, Canada.

ProMetic Life Sciences Inc (PLI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
ProMetic Life Sciences Acquires Plasma Collection Center in Canada from Emergent BioSolutions 14
Partnerships 15
Prometic Life Sciences to Form Joint Venture with Shenzhen Royal Asset Management 15
ProMetic Life Sciences Enters into Agreement with ProThera Biologics 16
ProMetic BioSciences Enters Into Co-Development Agreement With Pharma Company 17
ProMetic Life Sciences Enters Into Co-Marketing Agreement With Sartorius Stedim Biotech 18
ProMetic Life Sciences Enters Into Joint Venture Agreement With NantPharma 19
ProMetic Life Sciences Enters Into Co-Development Agreement With Hematech Biotherapeutics 20
Licensing Agreements 21
ProMetic Life Sciences Enters into Licensing Agreement with Omnio 21
Ipsen Enters into Licensing Agreement with Telesta Therapeutics 22
BL&H Enters into Licensing Agreement with Telesta Therapeutics 23
ProMetic Life Sciences Enters into Licensing Agreement with Generium 24
ProMetic Life Sciences Enters Into Licensing Agreement With Shenzhen Hepalink Pharma 25
ProMetic Life Sciences Enters Into Licensing Agreement For Its Affinity Resin Technology 26
Paladin Labs Enters Into Licensing Agreement With Bioniche Life Sciences 27
Equity Offering 29
Prometic Life Sciences Raises USD40.2 Million in Public Offering of Shares 29
Prometic Life Sciences Raises USD6.5 Million in Private Placement of Shares 31
ProMetic Life Sciences Raises USD16 Million in Private Placement of Shares upon Exercise of Warrants 32
ProMetic Life Sciences Raises USD3 Million in Private Placement of Shares 33
ProMetic Life Sciences Raises USD47.8 Million in Public Offering of Shares 34
Telesta Therapeutics Raises USD28.3 Million in Private Placement of Shares 36
Telesta Therapeutics Raises USD0.2 Million in Private Placement of Shares 37
ProMetic Life Sciences Announces Underwriters Exercise of Over-Allotment Option for USD7.5 Million Bought Deal Public Offering of Shares 38
ProMetic Life Sciences Announces Underwriters Exercise of Over-Allotment of Public Offering of Shares 39
Bioniche Life Sciences Raises USD5.2 Million in Public Offering of Units 41
ProMetic Life Sciences Completes Private Placement Of Shares For US$23 Million 43
Bioniche Life Sciences Completes Private Placement Of Units For US$9.4 Million 45
ProMetic Life Sciences Raises USD10 Million in Pivate Placement Of Shares 47
ProMetic Life Sciences Completes Private Placement Of Shares For US$1 Million 48
Debt Offering 49
ProMetic Life Sciences Raises USD30 Million in Private Placement of 8% Notes Due 2022 49
Acquisition 50
ProMetic Life Sciences Acquires Telesta Therapeutics 50
ProMetic Life Sciences Acquires Additional Stake In NantPro BioSciences 52
ProMetic Life Sciences Inc – Key Competitors 53
ProMetic Life Sciences Inc – Key Employees 54
ProMetic Life Sciences Inc – Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Recent Developments 57
Financial Announcements 57
Aug 14, 2018: Prometic Life Sciences announces second quarter 2018 financial results 57
May 15, 2018: Prometic Announces 2018 first quarter financial results 59
Mar 28, 2018: Prometic Reports its Q4-2017 and YE-2017 Financial Results and Provides Update on Activities 61
Nov 13, 2017: Prometic Reports 2017 Third Quarter Highlights and Financial Results 66
Aug 14, 2017: Prometic Reports 2017 Second Quarter Highlights and Financial Results 68
May 15, 2017: Prometic Reports 2017 First Quarter Highlights and Financial Results 70
Mar 30, 2017: Prometic Reports its 2016 Fourth Quarter and Year End Highlights and Financial Results 72
Corporate Communications 75
Apr 03, 2018: Prometic Announces Appointment of Bruce Wendel as Chief Business Development Officer 75
Product News 76
10/20/2017: Prometic Presents In Vivo Data for PBI-4547 at American Association for the Study of Liver Diseases (AASLD) Meeting 76
06/12/2017: Prometic Life Sciences Present Data on PBI-4547 at 2017 American Diabetes Association 77th Scientific Sessions 77
05/08/2017: Prometic to Present New Data on how Plasminogen Reduces Acute Lung Injury at the American Thoracic Society’s 2017 International Conference 78
05/08/2017: Prometic to Present New Data on PBI-4425 at the American Thoracic Society’s 2017 International Conference 79
Product Approvals 80
Mar 05, 2018: Prometic receives Rare Pediatric Disease Designation from U.S. FDA for its Inter-Alpha-Inhibitor-Proteins 80
Feb 15, 2018: Prometic granted orphan drug designation by FDA for Inter-Alpha-Inhibitor-Proteins for treatment of necrotizing enterocolitis (NEC) 81
Aug 29, 2017: Prometic Receives Rare Pediatric Disease Designation From U.S. FDA for its Plasminogen Replacement Therapy 82
Jul 11, 2017: Prometic Announces Positive Long Term Clinical Data on Ryplazym in Plasminogen Congenital Deficiency and Provides Regulatory Update 83
Apr 05, 2017: Prometic completes the filing of its plasminogen Biologics License Application with the U.S. FDA 84
Other Significant Developments 85
Feb 20, 2018: Prometic Announces Realignment of its Clinical Program Priorities for 2018 85
May 10, 2017: Prometic reports its 2017 annual and special meeting of shareholders highlights 87
Apr 07, 2017: Prometic Receives $9.5 Million Purchase Order From Multinational Client 89
Appendix 90
Methodology 90
About GlobalData 90
Contact Us 90
Disclaimer 90

List of Tables
ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
ProMetic Life Sciences Inc, Deals By Therapy Area, 2012 to YTD 2018 10
ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
ProMetic Life Sciences Acquires Plasma Collection Center in Canada from Emergent BioSolutions 14
Prometic Life Sciences to Form Joint Venture with Shenzhen Royal Asset Management 15
ProMetic Life Sciences Enters into Agreement with ProThera Biologics 16
ProMetic BioSciences Enters Into Co-Development Agreement With Pharma Company 17
ProMetic Life Sciences Enters Into Co-Marketing Agreement With Sartorius Stedim Biotech 18
ProMetic Life Sciences Enters Into Joint Venture Agreement With NantPharma 19
ProMetic Life Sciences Enters Into Co-Development Agreement With Hematech Biotherapeutics 20
ProMetic Life Sciences Enters into Licensing Agreement with Omnio 21
Ipsen Enters into Licensing Agreement with Telesta Therapeutics 22
BL&H Enters into Licensing Agreement with Telesta Therapeutics 23
ProMetic Life Sciences Enters into Licensing Agreement with Generium 24
ProMetic Life Sciences Enters Into Licensing Agreement With Shenzhen Hepalink Pharma 25
ProMetic Life Sciences Enters Into Licensing Agreement For Its Affinity Resin Technology 26
Paladin Labs Enters Into Licensing Agreement With Bioniche Life Sciences 27
Prometic Life Sciences Raises USD40.2 Million in Public Offering of Shares 29
Prometic Life Sciences Raises USD6.5 Million in Private Placement of Shares 31
ProMetic Life Sciences Raises USD16 Million in Private Placement of Shares upon Exercise of Warrants 32
ProMetic Life Sciences Raises USD3 Million in Private Placement of Shares 33
ProMetic Life Sciences Raises USD47.8 Million in Public Offering of Shares 34
Telesta Therapeutics Raises USD28.3 Million in Private Placement of Shares 36
Telesta Therapeutics Raises USD0.2 Million in Private Placement of Shares 37
ProMetic Life Sciences Announces Underwriters Exercise of Over-Allotment Option for USD7.5 Million Bought Deal Public Offering of Shares 38
ProMetic Life Sciences Announces Underwriters Exercise of Over-Allotment of Public Offering of Shares 39
Bioniche Life Sciences Raises USD5.2 Million in Public Offering of Units 41
ProMetic Life Sciences Completes Private Placement Of Shares For US$23 Million 43
Bioniche Life Sciences Completes Private Placement Of Units For US$9.4 Million 45
ProMetic Life Sciences Raises USD10 Million in Pivate Placement Of Shares 47
ProMetic Life Sciences Completes Private Placement Of Shares For US$1 Million 48
ProMetic Life Sciences Raises USD30 Million in Private Placement of 8% Notes Due 2022 49
ProMetic Life Sciences Acquires Telesta Therapeutics 50
ProMetic Life Sciences Acquires Additional Stake In NantPro BioSciences 52
ProMetic Life Sciences Inc, Key Competitors 53
ProMetic Life Sciences Inc, Key Employees 54
ProMetic Life Sciences Inc, Other Locations 55
ProMetic Life Sciences Inc, Subsidiaries 55

List of Figures
ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

★海外企業調査レポート[ProMetic Life Sciences Inc (PLI)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Alnylam Pharmaceuticals Inc (ALNY)-医療機器分野：企業M&A・提携分析
    Summary Alnylam Pharmaceuticals Inc, (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines; cardiova …
  • Banco Santander SA：戦略・SWOT・企業財務分析
    Banco Santander SA - Strategy, SWOT and Corporate Finance Report Summary Banco Santander SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Scotiabank Peru S.A.A.：企業の戦略・SWOT・財務分析
    Scotiabank Peru S.A.A. - Strategy, SWOT and Corporate Finance Report Summary Scotiabank Peru S.A.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Volt Information Sciences Inc (VOLT)：企業の財務・戦略的SWOT分析
    Volt Information Sciences Inc (VOLT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Hon Hai Precision Industry Co Ltd (2317)：企業の財務・戦略的SWOT分析
    Hon Hai Precision Industry Co Ltd (2317) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • SGD S.A.：企業の戦略・SWOT・財務情報
    SGD S.A. - Strategy, SWOT and Corporate Finance Report Summary SGD S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Virbac Corporation
    Virbac Corporation - Strategy, SWOT and Corporate Finance Report Summary Virbac Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • ManpowerGroup Inc (MAN)：企業の財務・戦略的SWOT分析
    ManpowerGroup Inc (MAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Exco Resources Inc (XCOOQ)：石油・ガス：M&Aディール及び事業提携情報
    Summary Exco Resources Inc (Exco Resources) is an oil and gas company that offers crude oil and natural gas. The company offers acquisition, exploration, development, exploitation, operations, management, and production of onshore natural gas and oil assets. It provides services such as portfolio re …
  • Dollar Tree Inc：企業の戦略・SWOT・財務情報
    Dollar Tree Inc - Strategy, SWOT and Corporate Finance Report Summary Dollar Tree Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • National Gas & Industrial Co (2080)：企業の財務・戦略的SWOT分析
    National Gas & Industrial Co (2080) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • C-Rad AB (CRAD B)：医療機器：M&Aディール及び事業提携情報
    Summary C-Rad AB (C-Rad) is a medical device company that develops, manufactures and markets advanced radiation therapy equipments. The company offers products and solutions for patient positioning, tumor localization, and radiation treatment systems. Its products include sentinel 4DCT, catalyst HD, …
  • Uranium One Inc：企業の戦略的SWOT分析
    Uranium One Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Sempra U.S. Gas & Power LLC-石油・ガス分野：企業M&A・提携分析
    Summary Sempra U.S. Gas & Power, LLC (Sempra US), a subsidiary of Sempra Energy, an energy solution provider, is a clean power solutions developer. It develops, designs, constructs and operates renewable energy and natural gas solutions, with a focus on zero and low emission fuels. The company owns …
  • Cre8tek Ltd (FGO)：石油・ガス：M&Aディール及び事業提携情報
    Summary Cre8tek Ltd (Cre8tek), formerly Marion Energy Ltd, is an oil and gas exploration and production company. The company explores, acquires, develops, produces and markets oil and gas. It has core operations in Clear Creek field located in the Uinta Basin. Cre8tek also holds interest in the addi …
  • ClearOne Inc (CLRO)：企業の財務・戦略的SWOT分析
    Summary ClearOne Inc (ClearOne) formerly ClearOne Communications Inc, is a technology company that provides conferencing, collaboration, streaming, and digital signage solutions. The company provides professional conferencing, audio and video distribution, premium conferencing, tabletop conferencing …
  • Summit Pharmaceuticals International Corp：企業の戦略的SWOT分析
    Summit Pharmaceuticals International Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Indiana University Health Inc：企業の戦略的SWOT分析
    Indiana University Health Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Crocs, Inc.：企業の戦略・SWOT・財務情報
    Crocs, Inc. - Strategy, SWOT and Corporate Finance Report Summary Crocs, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Tabuk Pharmaceuticals Manufacturing Company-製薬・医療分野：企業M&A・提携分析
    Summary Tabuk Pharmaceuticals Manufacturing Company (Tabuk), a subsidiary of Astra Industrial Group is a drug company that develops, manufactures and markets branded generic pharmaceuticals and under-licensed products . The company offers products in various therapeutic areas including alimentary tr …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆